Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1982 1
1985 2
1987 1
1988 6
1989 9
1990 4
1991 4
1992 2
1993 5
1994 5
1995 3
1996 8
1997 7
1998 13
1999 10
2000 19
2001 14
2002 13
2003 30
2004 34
2005 44
2006 55
2007 51
2008 75
2009 87
2010 85
2011 93
2012 110
2013 143
2014 200
2015 236
2016 257
2017 249
2018 318
2019 345
2020 431
2021 215
Text availability
Article attribute
Article type
Publication date

Search Results

2,882 results
Results by year
Filters applied: . Clear all
Page 1
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, Zhou X, Luo H, Mao Z, Chen X, Xie J, Liu J, Cheng H, Zhao J, Huang G, Wang W, Zhou J. Cao Y, et al. Among authors: mao z. J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3. doi: 10.1016/j.jaci.2020.05.019. Epub 2020 May 26. J Allergy Clin Immunol. 2020. PMID: 32470486 Free PMC article. Clinical Trial.
Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients.
Chen L, Long X, Xu Q, Tan J, Wang G, Cao Y, Wei J, Luo H, Zhu H, Huang L, Meng F, Huang L, Wang N, Zhou X, Zhao L, Chen X, Mao Z, Chen C, Li Z, Sun Z, Zhao J, Wang D, Huang G, Wang W, Zhou J. Chen L, et al. Among authors: mao z. Cell Mol Immunol. 2020 Sep;17(9):992-994. doi: 10.1038/s41423-020-0492-x. Epub 2020 Jul 3. Cell Mol Immunol. 2020. PMID: 32620787 Free PMC article. No abstract available.
2,882 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page